Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV)
APR-246 when given to patients with refractory hematologic malignancies or prostate
carcinoma.